Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized Subjects
Paused · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Vancomycin-Resistant Enterococcal Colonization
In brief
The study is a first-in-human Phase 1/2a randomized, double-blind, placebo-controlled trial to assess the clinical safety and efficacy of VRELysin in healthy and VRE-colonized adults.
Key facts
- Study ID
- NCT05715619
- Run by
- Intralytix, Inc.
- People needed
- 80
- Starts
- 2023-10-25
- Expected to finish
- 2026-10-31
- Last updated by the study team
- 2026-04-14
Who can join
Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.
Where it is running
- UPMC Presbyterian — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.